This company is no longer active
SELECT B Stock Overview
Selectimmune Pharma AB (publ), a pharmaceutical company, develops drugs for the treatment of acute and chronic infections.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Selectimmune Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.38 |
| 52 Week High | kr5.58 |
| 52 Week Low | kr1.20 |
| Beta | 1.21 |
| 1 Month Change | -0.42% |
| 3 Month Change | 5.78% |
| 1 Year Change | -48.71% |
| 3 Year Change | -83.92% |
| 5 Year Change | n/a |
| Change since IPO | -76.55% |
Recent News & Updates
Shareholder Returns
| SELECT B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 3.9% | -6.7% | -0.7% |
| 1Y | -48.7% | 60.6% | 8.7% |
Return vs Industry: SELECT B underperformed the Swedish Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: SELECT B underperformed the Swedish Market which returned -2.3% over the past year.
Price Volatility
| SELECT B volatility | |
|---|---|
| SELECT B Average Weekly Movement | 22.8% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SELECT B's share price has been volatile over the past 3 months.
Volatility Over Time: SELECT B's weekly volatility has increased from 18% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 2 | Gabriela Godaly | www.selectimmune.com |
Selectimmune Pharma AB (publ), a pharmaceutical company, develops drugs for the treatment of acute and chronic infections. The company products include IL-1 receptor antagonists, as well as NK1R, RNA Pol II, and IRF7 inhibitors. It has a collaboration agreement with Lonza to develop processes for NlpD, an immunotherapy protein.
Selectimmune Pharma AB (publ) Fundamentals Summary
| SELECT B fundamental statistics | |
|---|---|
| Market cap | kr41.55m |
| Earnings (TTM) | -kr8.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs SELECT B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SELECT B income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr8.65m |
| Earnings | -kr8.65m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 29, 2023
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SELECT B perform over the long term?
See historical performance and comparison